#1964 - Rick Doblin
NaN minutesEpisode #1964
Rick Doblin, Ph.D., is the Founder in 1986 and President of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit that wholly owns its pharmaceutical arm, MAPS Public Benefit Corporation (PBC), which has completed two highly successful Phase 3 studies of MDMA-assisted therapy for PTSD. MAPS PBC stands at a crossroads between obtaining the additional resources it needs from philanthropy, ensuring public benefit is foremost, or becoming a publicly traded company.
maps.org
Episodes with Rick Doblin
Episode Timestamps
Life on the Road and Performing in Clubs vs. Theaters
- Joe Rogan discusses his love for being on the road and performing in clubs
- Exploration of the difference in experience between clubs and theaters for comedians
- Anecdote about a drunk fan at a show in Dallas
Discussion on Civil Disobedience, Patriotism, and Psychedelic Therapy
- Personal account of civil disobedience and the rationale behind it during the 1970s
- Reflections on patriotism, military service, and standing up against unjust laws
- Impact of psychedelic therapy on veterans and the changing perception of psychedelics among diverse groups
Finding Common Ground and the Power of Psychedelic Experiences
- Importance of finding common ground and embracing opposing ideologies discussed with reference to Dave Chappelle's approach
- Exploration of how engaging in psychedelics can help break ideological barriers and foster acceptance of different viewpoints
- Joe Rogan shares personal experiences with psychedelics, particularly emphasizing the profound impact of DMT experiences
Breaking Patterns, Embracing the New, and Healing Through Psychedelics
- Discussion on the role of psychedelics in breaking habitual patterns and opening up to new experiences
- Emphasis on the transformative power of psychedelic experiences like 5MEO DMT in connecting with creation and challenging fixed perceptions
- Stories about Ibogaine usage, its potential benefits in treating addiction and PTSD, and its role in military interventions for healing
Ibogaine and its Potential in Treating Opiate Addiction
- Origins of Ibogaine use for withdrawal from opiates and its effectiveness
- Discussion on neuroplasticity and how psychedelics like Ibogaine promote new neural growth
- Challenges with current drug policies and the potential of Ibogaine in addressing the ongoing opioid crisis
Personal Journey with Psychedelics and Self-Discovery
- Experience with a combination of Ibogaine and LSD leading to self-reflection and realization
- The importance of self-criticism disconnected from self-hatred for personal growth
- Epiphany about acceptance of imperfections and learning from mistakes for future endeavors
PTSD, Depression, and Healing with Psychedelics
- Discussion on the impact of the stories we tell ourselves on mental health such as PTSD and depression
- Personal experience of spending days in a state of self-criticism and eventual openness after a psychedelic experience
- Advocacy for the medical use of psychedelics like Ibogaine for addiction treatment and the need for policy reform in drug scheduling
Drug Policy Reform and Psychedelic Research
- Exploration of the need for drug policy reform and the case for removing Ibogaine from Schedule 1
- Efforts by MAPS to advocate for the medical use of MDMA and Ibogaine and their potential impacts on public perception
- Discussion on the parallels between psychedelic research and drug policy changes in different states and the potential future evolution of drug laws
Drug Policy, Stigmatization, and Misinformation
- Discussion on the approach to drug legalization based on the level of danger
- Importance of providing support and treatment for individuals using dangerous drugs
- Critique of stigmatization and misleading information in media regarding drugs like MDMA
Vision for a Trauma-Free Future
- Explanation of the goal to achieve a world with net trauma by 2070
- Discussion on multi-generational impact of trauma and epigenetics
- Focus on mass mental health and spiritual evolution for humanity
Psychedelic Science Conference Overview
- Introduction of a special discount code for people interested in the psychedelic science conference
- Details about the conference, including the venue, speakers like Deepak Chopra, and support from government officials
- Expansion on the history and growth of the conference over the years, the theme of the current conference, and the discussion around for-profit psychedelic companies
Capitalization and Corporate Structure of MAPS
- Description of MAPS funding structure and its unique approach to raising capital
- Explanation of the public benefit corporation model and its application to pharmaceutical companies
- Success of MAPS's Phase 3 studies on MDMA therapy for PTSD and the statistical significance of the results
Controversy Surrounding MDMA Study and Neurotoxicity Claims
- Study by Johns Hopkins funded by National Institute on Drug Abuse claimed MDMA could harm dopamine and cause Parkinson's.
- Debate on the validity of the study findings and allegations of misleading information for grant money.
- Retraction of study after discovering that primates were given methamphetamine instead of MDMA, casting doubt on the entire research.
Scientific Research on MDMA and Neurotoxicity
- Researcher's personal involvement in spinal tap studies to investigate MDMA effects on neurotransmitters.
- Findings showing no dopamine damage in primates from MDMA consumption.
- Discussion on the misuse of scientific studies for financial gain rather than seeking the truth.
Psychedelic Drugs in the Middle Ages and Their Uses
- Discussion about the use of Scopolamine as a disorienting psychedelic drug like the Devil's Dust
- Exploration of Scopolamine's various applications from inducing suggestibility to preventing motion sickness
- Anecdotes and studies related to the use of LSD for psychological breakthroughs and its potential role in aiding alcohol use disorder treatment
The Good Friday Experiment and Mystical Experiences
- Overview of the Good Friday Experiment involving psilocybin to induce mystical experiences
- Connections made between mystical experiences, political action, and the reduction of fear of death
- Challenges faced in conducting follow-up research related to psychedelic experiences and the importance of considering both risks and benefits
Concerns About Vulnerability and Psychological Impact
- Discussion on psychological vulnerabilities and potential impact of experiences on individuals
- Importance of addressing vulnerabilities towards mental illnesses like schizophrenia
- Highlight on the risks of justifying morally reprehensible actions in the name of a cause
Education, Propaganda, and Drug Awareness
- Reflection on resistance to drug experiences and mental control over psychedelic effects
- Anecdote about the effects of edibles and varying individual reactions to cannabis products
- Issue of historical propaganda, societal influence, and the necessity of honest drug education
The Concord Prison Experiment with Psilocybin
- Timothy Leary's Concord Prison experiment using psilocybin in prisons to reduce recidivism
- Discovery of lost records of the experiment leading to a follow-up study in 1991
- Revelation of scientific fraud in the experiment's reported success and the need for proper support and aftercare
Psychedelic Therapy, Recidivism, and Support Programs
- Critique on the overvaluation of the psychedelic experience in reducing recidivism
- Discussion on the importance of support groups and aftercare in successful rehabilitation
- Rick Doblin's advocacy for integrating psychedelic therapy with counseling for effective reintegration into society
Current Status and Funding Challenges for MDMA Approval
- Discussion on the progress of Phase III studies for MDMA
- Financial challenges from present to FDA approval and achieving sustainability
- Debate on the potential risks and benefits of turning MAPS into a publicly traded company
Philanthropy vs. Capital Investment in MDMA Therapy
- Exploration of potential paths to accelerate MDMA legalization
- Funding requirements for FDA approval and moving towards sustainability
- Balancing public benefit and investor concerns in MDMA therapy development
Discovery of Bromo LSD for Cluster Headaches
- Joe Rogan encountered a patent attorney at a party through his wife's foundation work on education
- Discussion on the breakthrough of using LSD/psilocybin for cluster headaches and the project in Jordan
- Exploration of Bromo LSD's effectiveness in treating cluster headaches and the patent process
Data Exclusivity and the Future of MDMA as Medicine
- Introduction of data exclusivity concept and its significance in drug development without patents
- Explanation of the potential for MDMA to become medicine for PTSD and other disorders with data exclusivity
- Discussion on the strategy to achieve self-sustainability and reduce dependency on external funding through data exclusivity period
Challenges with MDMA Dosage Testing
- Study tested various doses of MDMA from 25mg to 150mg for therapeutic benefits
- Low doses of MDMA caused discomfort and less benefit compared to inactive placebo
- FDA meeting revealed the need for blinding to reduce bias and challenges in differentiating between low dose and no dose groups
Regulatory Approval and Future of Psychedelics
- Importance of random assignment and independent raters to reduce bias in experiments
- Discussion on FDA's consideration for therapy with inactive placebo for PTSD
- Outlook on regulation and approval process, bipartisan support, and potential future substances like psilocybin
Benefits of Going Public and Pricing Strategies in Pharmaceutical Industry
- Discussion on using equity investments as incentives for staff in a public company setting
- Exploration of creating a public benefit-driven model for the pharmaceutical industry by going public
- Challenges and considerations of pricing strategies in pharmaceutical industry for equitable access
Equitable Access and Legalization of Psychedelics
- Debate on equitable access to psychedelic therapy and the importance of combining therapy with drug treatment
- Exploration of drug legalization and its impact on criminal activities and public perception
- Pricing strategies related to insurance coverage and return on investment in pharmaceutical industry